Company Encyclopedia
View More
name
HeartSciences
HSCS.US
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc.
1.392 T
HSCS.USMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking139/175
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-220.46%E
    • Profit Margin-104237.92%E
    • Gross Margin58.33%B
  • Growth ScoreE
    • Revenue YoY-41.03%E
    • Net Profit YoY-18.52%D
    • Total Assets YoY-22.90%E
    • Net Assets YoY4.13%C
  • Cash ScoreD
    • Cash Flow Margin-0.10%D
    • OCF YoY-41.03%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio30.25%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Heart Test Laboratories: AI-Driven Cardiology Platform Nearing Regulatory Milestones Supports Upside and Buy Rating

    Ascendiant analyst Lucas Ward maintains a Buy rating on Heart Test Laboratories (HSCS) due to operational progress and upside potential. The company outperformed Q2 FY26 earnings expectations and is advancing its MyoVista Insights platform with AI capabilities. A recent 510(k) submission for MyoVista wavECG hardware is a key milestone, with FDA clearance expected in 2026. Despite financing and execution risks, Ward's analysis supports a price target of $9.20, triple the current share price. Maxim Group also reiterates a Buy rating with a $12.00 target.

    Tip Ranks·
    US
    HSCS
    +10.47%
    Tip Ranks·
    US
    HSCS
    +10.47%

    HeartSciences | 8-K: FY2026 Q2 Revenue: USD 0

    LB filings·
    US
    HSCS
    +10.47%
    LB filings·
    US
    HSCS
    +10.47%

    HeartSciences | 10-Q: FY2026 Q2 Revenue: USD 2.419 K

    LB filings·
    US
    HSCS
    +10.47%
    LB filings·
    US
    HSCS
    +10.47%

    Heart Test Laboratories Announces Successful Regulation A Offering

    Heart Test Laboratories, Inc. (HSCS) announced a successful Regulation A Offering, generating $6.7 million in gross proceeds as of October 1, 2025. The company extended its loan maturity date to September 30, 2026, and conducted a debt exchange, reducing principal and accrued interest by $2,105,000 for common stock. Analysts rate HSCS stock as Hold with a $3.50 price target, while Spark's AI Analyst considers it Neutral due to significant financial challenges and poor valuation. Current market cap stands at $9.06 million.

    Tip Ranks·
    US
    HSCS
    +10.47%
    Tip Ranks·
    US
    HSCS
    +10.47%

    Heart Test Laboratories Regains Nasdaq Compliance

    Heart Test Laboratories, Inc. (HSCS) has regained compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement after addressing a previous non-compliance notice. The company received an extension to submit a compliance plan, which has now been accepted by Nasdaq. Analysts rate HSCS stock as a Hold with a $3.50 price target, but the company faces significant financial challenges, including losses and declining revenue. Technical analysis indicates mixed signals, and the stock has a low overall score due to poor valuation and lack of dividend yield.

    Tip Ranks·
    US
    HSCS
    +10.47%
    Tip Ranks·
    US
    HSCS
    +10.47%
    © 2025 Longbridge｜Disclaimer